• Ginkgo customers will now have access to IdeeLab's local strain discovery capabilities, as well as the ability to manufacture next-generation products in IdeeLab's manufacturing facilities

PIRACICABA, Brazil, April 8, 2024 /PRNewswire/ -- IdeeLab Biotechnology, a Brazilian company aiming to develop innovations and biological solutions for agriculture, today announced that is has entered into an agreement with Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, to join the Ginkgo Technology Network.

The Ginkgo Technology Network is a groundbreaking global ecosystem of cutting-edge technology partners dedicated to driving innovation in customer R&D programs. Ginkgo plans to integrate the technological capabilities of its network partners to provide customers with more robust end-to-end solutions to drive successful R&D outcomes across biological end markets.

IdeeLab is leading sustainable agriculture biological products development in Brazil by developing new technologies on behalf of customers for the crop input market. Particularly noteworthy, in Q1 2025, IdeeLab will have the only plant in Brazil certified by regulators to make ag input metabolites and proteins from GMOs, which will enable next-generation products in agriculture, such as metabolite and peptide/protein-based biocontrol products that are potentially safer and more efficacious versus conventional chemicals. The manufacturing facility will eventually reach 6 million liters of fermentation capacity, which is more than enough to enable clients to do commercial derisking before potentially building out fermentation capacity of their own. 

IdeeLab's biotech platforms, pilot-scale facility and industrial setting will complement Ginkgo's cell engineering and discovery capabilities. With IdeeLab, customers can now work with Ginkgo in various capacities such as metabolite and microbial discovery through fermentation scale up, registration, field trialing, and manufacturing a product in the fast-growing Brazilian biologicals market.

Ginkgo will continue to add partners to the Technology Network to further complement its offerings, and enable more clients in Brazil to access and explore the joint capabilities of the integrated Technology Network. Ginkgo is already working with leading product developers in the Brazilian market, and more are expected to join with this new expansion.

Ronaldo José Durigan Dalio, CEO of IdeeLab: "This partnership with Ginkgo will help us leap into the future, and leverages both companies to deliver even more innovative solutions to the Brazilian market in a faster and more efficient way. IdeeLab has been leading the development of the next generation of bio ag input in Brazil, and connecting GInkgo's expertise to ours in this process will also help us explore new routes for improving both industrial production and product field performance for our clients."

Anna Marie Wagner, Ginkgo's SVP, Head of AI and Corporate Development: "IdeeLab has been inspiring a new era in Brazilian agriculture and we're thrilled to welcome them to the Ginkgo Technology Network! Adding IdeeLab to our network now gives us the complete, end-to-end ability to deliver ag biological products for customers, especially next-generation products that are based on proteins, peptides and metabolites."

About IdeeLab Biotechnology 

IdeeLab is a fast-growing innovative ag biotechnology company in Brazil, focused on developing disruptive biological technologies and products for sustainable and regenerative agriculture, including biocontrol of pests and diseases, induction of plant resistance/tolerance responses,biostimulation, nutritional cycling and modulation of biotic/abiotic stress in major crops. Our multidisciplinary approach enables us to address emerging needs of the global agriculture market, providing biotechnology-as-a-service along different stages of R&D, from Bioprospection and Discovery, to Agronomical Validation and Go-to-Market (scale up, formulation, shelf-life/quality control, technology transfer, and manufacturing). Our expertise in phytopathology, plant physiology, and biochemistry, and our laboratories and bioprocess facilities are tailored to serve the development of ag inputs based on microbial cell growth/spore titers, as well as metabolites, peptides/proteins, interference RNA, CRISPR-edited, and other GM-derived microorganisms. We are expanding these capabilities to an industrial setting dedicated exclusively to B2B production (white label), to be inaugurated at the end of 2024. For more information, visit www.ideelab.com.br, or follow us on social media channels Instagram
(@ideelab_biotech) and LinkedIn (www.linkedin.com/company/ideelabbr/).

IDEELAB BIOTECHNOLOGY CONTACT:

This email address is being protected from spambots. You need JavaScript enabled to view it.

About Ginkgo Bioworks

Ginkgo Bioworks is the leading horizontal platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Ginkgo's biosecurity and public health unit, Concentric by Ginkgo, is building global infrastructure for biosecurity to empower governments, communities, and public health leaders to prevent, detect and respond to a wide variety of biological threats. For more information, visitginkgobioworks.com andconcentricbyginkgo.com, read ourblog, or follow us on social media channels such as X (@Ginkgo and @ConcentricByGBW), Instagram (@GinkgoBioworks), Threads (@GinkgoBioworks) orLinkedIn.

GINKGO BIOWORKS INVESTOR CONTACT:
This email address is being protected from spambots. You need JavaScript enabled to view it.

GINKGO BIOWORKS MEDIA CONTACT:
This email address is being protected from spambots. You need JavaScript enabled to view it.